The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of NeuroPace Inc (NASDAQ: NPCE) was $17.99 for the day, up 5.82% from the previous closing price of $17.00. In other words, the price has increased by $5.82 from its previous closing price. On the day, 0.49 million shares were traded. NPCE stock price reached its highest trading level at $18.252 during the session, while it also had its lowest trading level at $16.5.
Ratios:
Our analysis of NPCE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.70 and its Current Ratio is at 6.63. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on January 21, 2025, initiated with a Buy rating and assigned the stock a target price of $17.
On March 14, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $16 to $20.
On January 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $22.Leerink Partners initiated its Outperform rating on January 30, 2024, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 14 ’25 when ORBIMED ADVISORS LLC sold 168,136 shares for $15.85 per share. The transaction valued at 2,665,333 led to the insider holds 3,238,199 shares of the business.
Morrell Martha sold 78,334 shares of NPCE for $1,074,844 on Feb 21 ’25. The CHIEF MEDICAL OFFICER now owns 81,993 shares after completing the transaction at $13.72 per share. On Feb 20 ’25, another insider, KCK LTD., who serves as the 10% Owner of the company, sold 5,270,845 shares for $9.40 each. As a result, the insider received 49,545,943 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NPCE now has a Market Capitalization of 590044992 and an Enterprise Value of 596935104. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.00 while its Price-to-Book (P/B) ratio in mrq is 24.28. Its current Enterprise Value per Revenue stands at 7.081 whereas that against EBITDA is -31.315.
Stock Price History:
The Beta on a monthly basis for NPCE is 2.22, which has changed by 1.265743 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, NPCE has reached a high of $17.85, while it has fallen to a 52-week low of $5.45. The 50-Day Moving Average of the stock is 47.33%, while the 200-Day Moving Average is calculated to be 76.49%.
Shares Statistics:
NPCE traded an average of 240.59K shares per day over the past three months and 449530 shares per day over the past ten days. A total of 32.75M shares are outstanding, with a floating share count of 22.63M. Insiders hold about 30.99% of the company’s shares, while institutions hold 61.05% stake in the company. Shares short for NPCE as of 1745971200 were 393663 with a Short Ratio of 1.64, compared to 1743379200 on 449552. Therefore, it implies a Short% of Shares Outstanding of 393663 and a Short% of Float of 2.0399998999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.09 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.53 and -$0.94 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.61, with 6.0 analysts recommending between -$0.34 and -$0.87.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $23.69M to a low estimate of $22.7M. As of the current estimate, NeuroPace Inc’s year-ago sales were $19.26MFor the next quarter, 7 analysts are estimating revenue of $24.32M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $23.6M.
A total of 7 analysts have provided revenue estimates for NPCE’s current fiscal year. The highest revenue estimate was $96.98M, while the lowest revenue estimate was $93M, resulting in an average revenue estimate of $94.75M. In the same quarter a year ago, actual revenue was $79.91MBased on 7 analysts’ estimates, the company’s revenue will be $106.48M in the next fiscal year. The high estimate is $116.63M and the low estimate is $101M.
